Objective:

To address the challenge of managing patients with both astigmatism and presbyopia, focusing on improving comfort, convenience, and visual performance through the introduction of a new contact lens option.

Key Findings:

• Astigmatism affects about half of patients in at least one eye, contributing to a significant need for effective management.
• Presbyopia is projected to impact up to 2.1 billion people globally by 2030, highlighting the urgency for suitable solutions.
• High dropout rates in contact lens wearers, with around one in four new wearers discontinuing use within the first year, are linked to dissatisfaction with vision quality and comfort.
• 91% first-fit success rate reported for the new lens, indicating strong initial acceptance.

Interpretation:

The launch of this lens addresses a significant gap in the market for patients with both astigmatism and presbyopia, responding to clinician demands for better management options and improved patient satisfaction.

Limitations:

• Clinical data will require further scrutiny as the lens enters wider use, particularly regarding long-term outcomes.
• Initial availability is limited to select practices in the UK and Ireland, with a broader rollout planned for spring 2026.

Conclusion:

The ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM represents a significant advancement in contact lens options for an underserved patient group, with potential to improve satisfaction and reduce dropout rates.